Unlike general health products stocked in every health store, CJC-1295 reaches researchers through a specialist research supply market that Adea residents reach through online vendors. This global online supply model is actually an advantage for quality — top vendors compete on lab-verified purity in ways brick-and-mortar outlets simply cannot. What genuinely separates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety documentation. The sections below cover what Adea researchers need to know about purchasing, testing, and working with CJC-1295 for scientific research use.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Adea comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Quality CJC-1295 sourcing begins with a useful first test: does this vendor publish batch-specific COAs proactively? Vendors who do are signalling genuine quality commitment. The HPLC analytical chromatogram is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with small or absent impurity peaks representing impurities — purity should be stated as ≥98%. Community reputation in research forums is a complementary signal to COA verification — vendors with consistently positive reports over 12+ months have proved themselves through consistent results. Price is an unreliable primary filter for CJC-1295 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Adea
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human use by the FDA or comparable health authorities — all information here is for educational purposes only. Proper handling of CJC-1295 requires sterile reconstitution technique — prep pad-cleaned septum, single-use needles, uncontaminated workspace — and cold chain maintenance from receipt through use. The primary quality-related safety risk in CJC-1295 research is bacterial endotoxin from low-quality material — a documented endotoxin result in your specific batch certificate is the specific protection against this risk. Protocol documentation — recording exactly what was used, when, and how — is a sound practice for any CJC-1295 protocol that makes anomalous results interpretable.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
